ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019:

Cantor Fitzgerald Global Healthcare Conference – New York Friday, October 4, 2019, 1:10 PM ETPresentation: William H. Collier

Chardan Genetic Medicines Conference – New YorkMonday, October 7, 2019, 8:00 AM ETFireside Chat: William H. Collier and Dr. Gaston Picchio

Live webcasts of the presentations can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.  A replay of the webcasts will be available for 90 days following the live presentations.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

InvestorsWilliam H. Collier President and CEO Phone: 604-419-3200 Email: ir@arbutusbio.com MediaPam Murphy Investor Relations Consultant Phone: 604-419-3200 Email: ir@arbutusbio.com